ASCO21 Annual Meeting: Editors’ highlights

Written by Jade Parker, Senior Editor

asco annual meeting higlights

The American Society for Clinical Oncology (ASCO) Annual Meeting took place in a virtual format on 4−8 June 2021. Over the 4 days, pivotal data from trials and labs was presented from across the globe, to continue to advance the oncology field and patient outcomes. Find our highlights from the meeting below.

News highlights

IMpower010: Tecentriq® improves disease-free survival for some early lung cancer patients

Interim data from the IMpower010 Phase III clinical trial demonstrated that Tecentriq (atezolizumab) following surgery and chemotherapy reduces the risk of disease-free survival by 34% in patients with Stage II-IIIA NSCLC, whose tumors express PD-L1 ≥1%, compared with best supportive care.

Find out more in our interview here.

OlympiA: olaparib improves disease-free survival in high-risk, early-stage HER2-negative breast cancer with BRCA 1/2 mutations

The OlympiA Phase III trial has reported that olaparib offered a 3-year invasive disease-free survival of 85.9% in high-risk, early stage HER2-negative breast cancer patients harboring BRCA 1/2 mutations. The positive results may have implications for the standard of care in the adjuvant setting for this patient group.

Phase II trial shows new CAR-T therapy is viable in acute lymphoblastic leukemia patients

In a new Phase II ‘ZUMA-3’ study a novel chimeric antigen receptor (CAR) T-cell therapy known as Tecartus has been evaluated in patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Find out more on RegMedNet.

OUTBACK Phase III trial: stick with standard of care for locally advanced cervical cancer

Adjuvant chemotherapy alongside the standard of care chemoradiation provides no benefit for locally advanced cervical cancer patients.

Read the full news story. 

Targeted radiotherapy for previously treated metastatic castration-resistant prostate cancer

Targeted radiotherapy lutetium-labeled PSMA-617 (177Lu PSMA-617), significantly improved radiographic progression-free survival and overall survival when added to standard of care treatment in patients with metastatic castration-resistant prostate cancer (mCRPC).

Discover more details here. 

Want regular meeting updates straight to your inbox? Become a member of Oncology Central.

SPEARHEAD-1: engineered TCR therapy yields promising results for synovial sarcoma

Adaptimmune Therapeutics plc (UK) reported initial data from its Phase II SPEARHEAD-1 open-label trial evaluating afami-cel for individuals with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Find out more. 

CheckMate 648: single and dual immunotherapy improves overall survival for some advanced esophageal cancer patients

The Phase III CheckMate 648 trial has shown that compared to standard of care chemotherapy, both a dual immunotherapy regimen (nivolumab plus ipilimumab) and a single immunotherapy agent (nivolumab) added to chemotherapy extends overall survival for patients with advanced esophageal squamous cell carcinoma, particularly those positive for the immune checkpoint protein PD-L1.

Read the full news story

RELATIVITY-047: inhibiting LAG-3 plus PD-1 improves PFS for some melanoma patients

Data from the Phase II/III RELATIVITY-047 trial has demonstrated that a fixed-dose combination of relatlimab (LAG-3-blocking antibody) and nivolumab yields a clinically meaningful progression-free survival benefit compared to Opdivo® (nivolumab) alone in patients with previously untreated metastatic or unresectable melanoma.

Find out more. 

KEYNOTE-564 demonstrates that Keytruda® extends disease-free survival in clear-cell renal cell carcinoma

Findings from the Phase III KEYNOTE-564 trial have demonstrated that post-surgery treatment with Keytruda® (pembrolizumab) extends disease-free survival (DFS) for clear cell renal cell carcinoma (RCC) patients. The data supports adjuvant pembrolizumab as a potential new standard of care to reduce disease recurrence in patients with fully resected intermediate to high-risk RCC.

Read the full news story.

JUPITER-02: toripalimab extends progression-free survival in advanced nasopharyngeal carcinoma

The addition of the immunotherapy agent toripalimab to emcitabine-cisplatin chemotherapy as first-line treatment significantly delays disease progression for recurrent or metastatic nasopharyngeal carcinoma patients.

Find out more. 

Exclusive insights

Exploring the IMpower010 trial data, an interview with Charlie Fuchs


MYLUNG Consortium: characterizing barriers to comprehensive biomarker testing, an interview with Makenzi Evangelist4


ASCO 2021: what should you look out for?

Social media


For the latest conference news, visit our Events Coverage page now!